Researchers at the universities of “Duke”, “Texas” and American “Arkansas” have managed to develop a new strategy to increase the recording of adult medicine in cancer cells, increasing its effectiveness by 23 times. The study, published in the cell (cell), focuses on a promising group of revolutionary medicine, called “Protacs”, which is known for their ability to destroy cancer proteins. And ‘stimulants to get rid of targeted protein’ are an innovative group of treatments that work in a smart way that is completely different from traditional medicine. Instead of just preventing or obstructing pathogenic protein, these drugs direct the natural cleaning mechanism within cells to completely destroy these proteins. But her biggest problem was the trouble of cutting the cells due to the large size, which is more than 1000 Dalton, while the traditional limit of effective medicine is 500 Dalton. A new chemical technique and the research team have benefited from a protein found on the surface of cells called CD36, and is responsible for helping cells to “swallow” large molecules through a process known as ‘cellular retirement’. Using a new chemical technique, they called it “recovery of medicine chemistry”, and scientists designed a modified Protac to stick to the CD36 protein, which enabled them to enter cells with a higher efficiency of 7.7 to 22.3 times compared to traditional methods. ‘Cellular retirement’ and the technique of receptive pharmaceutical chemistry is a revolutionary approach in the design of medicine, which depends on the exploitation of a natural process known as cellular retirement, where the ‘swallow’ cells of external molecules’ form the formation of membranes. This strategy is radically different from the traditional methods that depend on the negative spread of small molecules by cell membranes. The strength of that technique lies in the ability to facilitate the entry of great medicine by holding on to specific membranes acting as active “entrance doors”. The new technology can solve one of the biggest challenges in the pharmaceutical industry, which is the trouble of connecting large and complicated molecules in the cells, which opens the door for a new generation of treatments previously excluded due to size, and the development of more effective medicine against adapted diseases such as cancer, neurological degenerative diseases, with the possibility of great treatments and molecules. The effectiveness of medicine against crops and the researchers has succeeded in improving the effectiveness of medicine against crops to 23 times by improving their selabsorption using the CD36 road, while maintaining the stability of medication and their solubility, and experiments on mice showed stronger braking with cancer cells without the side effects. This revolutionary medicine works by utilizing the CD36 protein on the surface of the cells, acting as a “back door” to help cells take up large molecules. With the entry of his entry, the pharmaceutical molecules are specifically targeted, “with a” brand “to destroy the Jodicein Bottazom system in the cell.” An exact vital mechanism is the ‘iodocoin brotazom’ system is a delicate life mechanism within the cells, which serves as a ‘recycling system’ of damaged or unmarked protein, where these protein is labeled “iodicoin” by a series of enzymatic reactions. Imbalance is related to cancer and neurological degenerative diseases. The researchers say this discovery is not only an improvement in the delivery of medication, but rather a fundamental change in the philosophy of its design, which opens the door for a new generation of treatments that were impossible in the past. The lead author of the study, Hong-Yi Li, a researcher at the University of “Texas”, says that for the first time the study that large molecules can enter cells effectively “, and that changes everything. Despite the impressive success of the study in laboratories, and in animal experiments, the application of these therapeutic techniques says to judge the patients.
It reaches 23 times .. Scientists develop a ‘revolutionary’ method to improve the effectiveness of cancer medication
